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Rapid progression of synchronous ovarian and endometrial cancers
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Accepted 13 October 2011We present a rare case of a 41-year-old woman with
synchronous primary cancers of the endometrium and ovary,
both in advanced stages. Palliative surgery with incomplete
tumor debulking followed by the first trial of chemotherapy
provided no treatment benefit to her prognosis and she died
shortly thereafter.
A 41-year-old woman, para 1, was referred to our department
for prolonged and profuse menstrual bleeding, poor appetite and
marked abdominal distension. Abdominal ultrasound and
computed tomography showed a large left adnexal tumor
accompanied by massive ascites and carcinomatosis (Fig. 1).
The levels of tumormarkers, including cancer antigen (CA) 125,
CA 19-9, and carcinoembryonic antigen (CEA), were 1588 U/
mL, 21 U/mL, and 1.4 ng/mL, respectively. During her opera-
tion, we noted a huge omental cake of about 35 cm (Fig. 2), a left
ovarian tumorwith rectal serosa invasion, diffuse intraperitoneal
(including bowels) tumor implantation, and massive ascites
totaling about 6600 mL. The uterus, the contralateral ovary and
tube, and the liver surface were not involved.
Suboptimal debulking surgery was done (residual tumor
size > 1 cm), and the estimated blood loss was 2000 mL. The
microscopic findings included two synchronous tumors of the
left ovary and endometrium. The histological types were
mixed clear cell (moderately differentiated), endometrioid
(well-differentiated) carcinoma of the left ovary (90% clear
and 10% endometrioid), and mucinous (moderately differen-
tiated) carcinoma of the endometrium, respectively. The
contralateral ovary revealed a microscopic tumor implant. The
final histopathological findings were synchronous ovarian
clear celleendometrioid carcinoma and endometrial mucinous
carcinoma, with massive omental carcinomatosis, without
lymph nodes metastasis, FIGO IIIC (pT3cN1) (Figs. 3 and 4).
She received adjuvant chemotherapy with carboplatin and
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respectively, after the operation and during chemotherapy.
However, she suffered from poor appetite, abdominal disten-
sion, and a weight increase at the third month after the oper-
ation. The tumor markers CA 125 and CA 19-9 were elevated
again (455 U/mL and 303 U/mL, respectively). Abdominal
computed tomography showed peritoneal carcinomatosis with
moderate ascites, along with irregular wall thickening of the
transverse colon, about 9.7 cm in length, resulting in severe
bowel obstruction. We proceeded with conservative treatment
that included antibiotics and fluid supplements, but her
condition rapidly worsened. She passed away on the 14th day
after her second admission (3 months after her operation).
Synchronous primary cancers of the endometrium and ovary
(SPCEOs) are uncommon, and the ovarian histology was endo-
metrioid in 92% of these cases. Among the cases of coexistent
ovarian involvement, 69% occurred in patients with grade 1
endometrial cancer, and 58% occurred with inner myometrial
invasion. Careful preoperative and intraoperative assessment of
the adnexa is mandatory in young women with endometrial
cancer. Those who desire ovarian preservation should be coun-
seled regarding the high rate of coexistent ovarianmalignancy [1].
The cause of simultaneously arising neoplasms has yet to be
elucidated. It has been suggested that embryologically similar
tissues, such as those of the female genital tract, may be subject
to the same carcinogenic or hormonal stimuli and thereby
develop synchronous neoplasms. This phenomenon of
synchronously arising malignancies of the female genital tract
seems to be more commonly seen in premenopausal than post-
menopausal women [2]. The occurrence of multiple malignan-
cies decades earlier than expected raises the question of genetic
susceptibility. Until now, we have not found any family histories
that were clearly suggestive of an inherited genetic syndrome.
However, the unusual characteristics of such patients, including
the high incidence of concordant endometrioid histology [3,4]
and the young age at the onset of malignancy, warrant further
investigation. In the general population, endometrioid histology
accounts for 16e24% of the epithelial ovarian carcinomas [4,5].cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 2. Huge omental cake of about 35 cm and the main tumor about 20 cm from the left ovary.
Fig. 1. Diffuse peritoneal carcinomatosis and massive ascites (A). A large locular cystic mass, 14.7 cm 14 cm, with a solid component in the left adnexa, favored
of left ovarian origin (B). Enlarged uterus with some debris in the cavity (C).
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concurrently with type 1 endometrial cancers were endome-
trioid or adenosquamous, and some showed as high as 88%Fig. 3. Mucinous carcinoma of the endometrium.endometrioid ovarian histology [4]. Although no stimulating
factor has been described to account for the effect, estrogens [6],
androgens [2] and endometriosis [7,8] have been hypothesized
as possible contributing factors.
The most common presenting symptom has been abnormal
vaginal bleeding, as in both of the tumors presented here.
During the past two decades, maximum cytoreductive surgery
(also called debulking surgery; residual tumor is  1 cm) has
been the recommended surgical approach for advanced stages
of ovarian carcinoma. The residual tumor volume after surgery
is one of the strongest prognostic factors, and only patients
who undergo complete or optimal surgery are likely to survive
long term (i.e., 50% after 5 years). A well-trained surgeon in
the field of gynecological oncology can achieve an optimal
tumor reduction in up to 75% of patients with advanced stage
ovarian cancer. During the procedure, bowel resection, espe-
cially rectosigmoid, must be undertaken in 30e40% of cases,
and para-aortic and pelvic lymphadenectomy should be
Fig. 4. (A) Clear cell carcinoma of the ovary (90%). (B) Endometrioid carcinoma of the ovary (10%).
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abdominal cavity. In advanced ovarian cancer patients, many
studies have demonstrated that cytoreduction to 1e2 cm
residual volume does not offer a significant survival advantage
as compared to those with > 2 cm residual volume. The
current Gynecologic Oncology Group definition of optimal
residual volume is  1 cm [9e12].
Very advanced cancer with massive peritoneal carcinoma-
tosis and/or stage IV disease requires an aggressive surgical
procedure but yields a poor prognosis and a higher risk of
unacceptable complications. For these worst cases, the concept
of cytoreductive surgery is moving toward the alternative
strategy of chemosurgical cytoreduction, in which interval
cytoreductive surgery is undertaken after three cycles of front-
line chemotherapy. The goal of this experimental strategy is to
achieve a complete tumor response after front-line chemo-
surgical therapy, and a better quality of life [13]. The Scottish
Randomized Trial in Ovarian Cancer (SCOTROC) was an
excellent trial, adding important information to our knowledge
regarding chemotherapy for ovarian cancer. However, its
attempt to analyze the benefit of aggressive surgery, which was
not an endpoint of the trial, by retrospectively using unclear
and faulty definitions and a nonvalidated, preoperative prog-
nostic model, is significantly flawed. The notion that per-
forming bowel resection and/or pelvic/para-aortic node
dissection to achieve optimal ( 1 cm residual) cytoreduction
is too aggressive is not supported by the data in this study or
any other. It is the concept itself e that the need to perform
such procedures is an indication of poor tumor biology e
which should be abandoned, not the cytoreductive procedures
themselves.
Patients diagnosed with a single primary tumor with
metastasis (SPM) have a significantly worse survival rate than
patients with dual primary tumors (SPCEOs). Patients in
whom both tumors are of endometrioid histology survive
longer than patients with other histological subtypes, and
patients diagnosed with SPM have a worse survival rate if the
mode of spread is from the ovary to the endometrium rather
than vice versa. Genetic analysis may represent a powerful
tool for use in clinical practice to distinguish between SPM
and SPCEO in patients with synchronous ovarian/endometrial
cancer and to predict disease outcome [14].For the case we presented here, no obvious family history
could be determined. Genetic analysis is strongly suggested
for her family in the future.References
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